Royal Bank of Canada
ESPR

Royal Bank of Canada’s Esperion Therapeutics ESPR Stock Holding History

Royal Bank of Canada’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2K Sell
831
-7,745
-90% -$24.5K ﹤0.01% 6688
2025
Q4 		$32K Sell
8,576
-900,657
-99% -$2.91M ﹤0.01% 5792
2025
Q3 		$2.41M Sell
909,233
-257,288
-22% -$498K ﹤0.01% 3243
2025
Q2 		$1.15M Buy
1,166,521
+1,159,846
+17,376% +$1.16M ﹤0.01% 3775
2025
Q1 		$10K Sell
6,675
-11,707
-64% -$21.6K ﹤0.01% 6149
2024
Q4 		$40K Sell
18,382
-1,178
-6% -$2.75K ﹤0.01% 5792
2024
Q3 		$32K Sell
19,560
-127,516
-87% -$257K ﹤0.01% 5886
2024
Q2 		$326K Buy
147,076
+103,280
+236% +$243K ﹤0.01% 4350
2024
Q1 		$117K Hold
43,796
– – ﹤0.01% 5097
2023
Q4 		$131K Buy
43,796
+33,763
+337% +$43.8K ﹤0.01% 5439
2023
Q3 		$10K Sell
10,033
-7,140
-42% -$10.3K ﹤0.01% 6410
2023
Q2 		$24K Sell
17,173
-5,055
-23% -$7.06K ﹤0.01% 6113
2023
Q1 		$36K Buy
22,228
+2,851
+15% +$14.7K ﹤0.01% 5788
2022
Q4 		$121K Buy
19,377
+17,789
+1,120% +$127K ﹤0.01% 5307
2022
Q3 		$10K Buy
1,588
+454
+40% +$3.12K ﹤0.01% 6418
2022
Q2 		$7K Sell
1,134
-3,189
-74% -$18.1K ﹤0.01% 6516
2022
Q1 		$19K Sell
4,323
-1,477
-25% -$6.33K ﹤0.01% 6636
2021
Q4 		$29K Buy
5,800
+101
+2% +$809 ﹤0.01% 6631
2021
Q3 		$67K Sell
5,699
-851
-13% -$12.4K ﹤0.01% 5980
2021
Q2 		$140K Buy
6,550
+2,699
+70% +$65K ﹤0.01% 5367
2021
Q1 		$108K Sell
3,851
-210
-5% -$6.2K ﹤0.01% 5406
2020
Q4 		$106K Buy
4,061
+1,751
+76% +$52.5K ﹤0.01% 5310
2020
Q3 		$86K Sell
2,310
-239
-9% -$9.47K ﹤0.01% 5054
2020
Q2 		$130K Buy
2,549
+42
+2% +$1.76K ﹤0.01% 4692
2020
Q1 		$79K Sell
2,507
-2,294
-48% -$121K ﹤0.01% 4918
2019
Q4 		$287K Buy
4,801
+2,514
+110% +$113K ﹤0.01% 4374
2019
Q3 		$83K Sell
2,287
-651
-22% -$25.8K ﹤0.01% 4890
2019
Q2 		$137K Buy
2,938
+811
+38% +$38.1K ﹤0.01% 4700
2019
Q1 		$86K Buy
2,127
+54
+3% +$2.42K ﹤0.01% 4862
2018
Q4 		$96K Sell
2,073
-10,106
-83% -$487K ﹤0.01% 4739
2018
Q3 		$541K Sell
12,179
-1,056
-8% -$48.5K ﹤0.01% 3860
2018
Q2 		$519K Buy
13,235
+11,962
+940% +$604K ﹤0.01% 3759
2018
Q1 		$92K Sell
1,273
-64
-5% -$4.7K ﹤0.01% 4742
2017
Q4 		$88K Sell
1,337
-1,846
-58% -$99.4K ﹤0.01% 4882
2017
Q3 		$160K Buy
3,183
+2,150
+208% +$104K ﹤0.01% 4671
2017
Q2 		$48K Sell
1,033
-1,237
-54% -$45.5K ﹤0.01% 5137
2017
Q1 		$80K Sell
2,270
-5,106
-69% -$117K ﹤0.01% 4885
2016
Q4 		$93K Buy
7,376
+286
+4% +$3.4K ﹤0.01% 4906
2016
Q3 		$99K Buy
7,090
+1,300
+22% +$14.7K ﹤0.01% 4828
2016
Q2 		$58K Sell
5,790
-250
-4% -$4.14K ﹤0.01% 5043
2016
Q1 		$102K Sell
6,040
-365
-6% -$5.87K ﹤0.01% 4746
2015
Q4 		$143K Buy
6,405
+1,489
+30% +$37.6K ﹤0.01% 4741
2015
Q3 		$116K Sell
4,916
-724
-13% -$45.4K ﹤0.01% 4690
2015
Q2 		$461K Buy
5,640
+4,420
+362% +$433K ﹤0.01% 3676
2015
Q1 		$113K Sell
1,220
-18,380
-94% -$1.19M ﹤0.01% 4547
2014
Q4 		$792K Buy
+19,600
New +$600K ﹤0.01% 3126
2014
Q2 		– Sell
-2,250
Closed -$34K – 5980
2014
Q1 		$34K Hold
2,250
– – ﹤0.01% 5009
2013
Q4 		$31K Buy
2,250
+850
+61% +$12.4K ﹤0.01% 5082
2013
Q3 		$27K Buy
+1,400
New +$23.5K ﹤0.01% 5067

Other funds holding ESPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's ESPR Position: Q1 2026 in Review

Royal Bank of Canada reduced its Esperion Therapeutics (ESPR) stake by 90% in Q1 2026, selling an estimated $24.5K and leaving 831 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6688.

Royal Bank of Canada first reported a position in ESPR in Q3 2013 and has held it in 49 quarters since. The position peaked at $2.41M in Q3 2025. 205 funds tracked by Wall St. Rank hold ESPR as of Q1 2026.

  • Royal Bank of Canada held 831 shares of Esperion Therapeutics worth $2K as of Q1 2026.
  • Royal Bank of Canada sold 7,745 Esperion Therapeutics shares in Q1 2026, an estimated $24.5K.
  • Esperion Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6688 holding.
  • Royal Bank of Canada first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 49 quarters since.
  • Royal Bank of Canada's Esperion Therapeutics position peaked at $2.41M in Q3 2025.
  • 205 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.